

Market Movers

12:52 01 Mar 2019

Small-Cap Snapshot: Lexicon Pharmaceuticals rallies as European agency recommends approval of diabetes treatment

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) gained after a European agency advanced a diabetes treatment that the company developed with Sanofi SA (NASDAQ:SNY). The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of sotagliflozin in the EU for both a 200- and 400-milligram dose as part of insulin therapy to improve blood sugar control in some adults with Type 1 diabetes.

Shares of Lexicon were up 27% to \$6.76 in Nasdaq trading. Sanofi gained 1.4% to \$42.20.

Colony Capital Inc (NYSE:CLNY) dropped after the Los Angeles-based financial services company reported fourth-quarter net investment losses of \$29 million. Total revenue dropped to \$634 million from \$720 million a year earlier.

The stock was down 3.6% to \$5.36 in New York.

READ: Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate

Puma Biotechnology Inc (NASDAQ:PBXI) surged after the biopharmaceutical company beat Wall Street's fourth-quarter estimates thanks to sales of its flagship breast-cancer drug Nerlynx. The company's net loss shrank to \$0.32 per share from \$1.03 a year earlier. It posted revenue of \$71.1 million, of which \$61.1 million was from Nerlynx and \$10 million was from license revenue. Analysts had expected Puma to lose \$0.69 on revenue of \$53.65 million.

Shares climbed 40% to \$39.02 in Nasdaq trading.

Intrexon Corp (NASDAQ:XON) sank after the Germantown, Maryland, biotech posted a fourth-quarter loss \$0.21 per basic share on total revenue of \$43.2 million, a decrease of 44% from a year earlier. Cash, cash equivalents and short-term investments totaled \$222.5 million.

The stock tumbled 36% to \$5.09 on the Nasdaq.

The Russell 2000 index of small-cap stocks edged up 0.3% to 1580.26.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.